Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2014
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 January 2012Published: 24 January 2007
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2010
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 April 2006
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 25 September 2017Published: 29 March 2017
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 January 2012
Colon cancer (adjuvant) - irinotecan [ID379]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 January 2021
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fruquintinib for previously treated metastatic colorectal cancer ID6274Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 May 2003
Laparoscopic surgery for colorectal cancer (TA105)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 August 2006
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 May 2020
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 July 2021
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 29 March 2017Published: 14 December 2011
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 September 2023
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 February 2015
Regorafenib for previously treated metastatic colorectal cancer (TA866)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 February 2023
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 August 2016
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 September 2024
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC